


Substitute for form 1449/PTO  
(Revised 04/2003)

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1** of **1** Attorney Docket Number **046562/274661**



## **Complete if Known**

Application Number **10/799,490**  
Filing Date **March 12, 2004**  
First Named Inventor **Karl Bruce Thor**  
Group Art Unit **1614**  
Examiner Name **Not yet assigned**

## **U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
/CH/	1	EP 0 814 084 A1 /	12-29-1997	Eli Lilly and Company		
/CH/	2	WO 00/44376 /	08-03-2000	Bristol-Myers Squibb Company		
/CH/	3	WO 00/72832 A2 /	12-07-2000	Merck Patent GMBH		
/CH/	4	WO 01/46179 A1 /	06-28-2001	Lilly and Company		
/CH/	5	WO 02/085911 A1 /	10-31-2002	Wyeth		
/CH/	6	WO 02/088144 A2 /	11-07-2002	Wyeth		
/CH/	7	WO 02/088146 A2 /	11-07-2002	Wyeth		


## **OTHER DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
/CH/	8	AHLENIUS, S. and LARSSON, K., "Synergistic actions of the 5-HT <sub>1A</sub> receptor antagonist WAY-100635 and citalopram on male rat ejaculatory behavior," <i>European Journal of Pharmacology</i> , 1999, pp. 1-6, Vol. 379.	
/CH/	9	SCHERER, T., <i>et al.</i> , "Synthesis and exploratory photophysical investigation of donor-bridge-acceptor systems derived from N-substituted 4-piperidones," <i>Recueil des Travaux Chimiques des Pays-Bas</i> , October 1993, pp. 535-548, Vol. 112.	
/CH/	10	WALDINGER, M.D., <i>et al.</i> , "Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system," <i>Behavioural Brain Research</i> , 1998, pp. 111-118, Vol. 92.	
Examiner Signature		Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
RTA01/2160968v1

Examiner Signature	/Carlic Huynh/	Date Considered	06/15/2007
--------------------	----------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003)				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number		10/799,490	
		Filing Date		March 12, 2004	
		First Named Inventor		Thor	
		Group Art Unit		1614	
		Examiner Name		Not yet assigned	
Sheet	1	of	1	Attorney Docket Number 046562/274661	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
/CH/	11	EP 1 008 594 A	06-14-2000	Vita Invest SA		

OTHER DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	English Language Translation Attached
/CH/	12	MARTINEZ, J., <i>et al.</i> , "New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl) Propane Derivatives with Dual Action at 5-HT <sub>1A</sub> Serotonian Receptors and Serotonin Transporter as a New Class of Antidepressants," <i>Eur. J. Med. Chem.</i> 2001, pp. 55-61, Vol. 36.	
/CH/	13	ORUS, L., <i>et al.</i> , "New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl) Propane Derivatives with Dual Action at 5-HT <sub>1A</sub> Serotonian Receptors and Serotonin Transporter as a New Class of Antidepressants," <i>Pharmazie</i> , 2002, pp. 515-518, Vol. 57(8).	
/CH/	14	ORUS, L., <i>et al.</i> , "Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-Propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT <sub>1A</sub> Receptors," <i>J. Med. Chem.</i> , 2002, pp. 4128-4139, Vol. 45.	
/CH/	15	ORUS, L., <i>et al.</i> , "New 3-[4-(aryl)piperazin-1-yl]-1-(benzo[b]thiophen-3-yl) Propane Derivatives with Dual Action at 5-HT <sub>1A</sub> Serotonian Receptors and Serotonin Transporter as a New Class of Antidepressants," <i>Pharmazie</i> , 2002, pp. 355-361, Vol. 57(6).	
Examiner Signature		Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
RTA01/2169178v1

Examiner Signature	/Carlic Huynh/	Date Considered	06/15/2007
--------------------	----------------	-----------------	------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.